Skip to Content
Merck
HomeCancer ResearchAuthenticated Lung Cancer Cell Lines for Cancer Research

Authenticated Lung Cancer Cell Lines for Cancer Research

Lung cancer is the leading cause of cancer-related death. Patients are frequently diagnosed at an advanced stage due to a relative lack of clinical symptoms. Lung cancer accounts for 13.2% of all new cancers and 25.9% of all cancer deaths each year. The overall five-year survival rate of lung cancer is lowest (18.1%) when compared to most other cancers1, but prognosis varies dramatically with pathological classification, disease stage, and patient demographics such as gender and age at diagnosis.

Types of lung cancer

The pathological classification of lung cancer is evolving. It is currently histopathologically classified into small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC)—which includes squamous cell carcinoma and adenocarcinoma. NSCLC, sometimes referred to as large cell lung carcinoma, accounts for the majority (85%) of lung cancer diagnoses.

Risk factors

The incidence of lung cancer is declining in developed countries, due in part to smoking education and regulation. Incidence rates are rising, however, in less developed countries. That 80% of men and 50% of women with lung cancer are smokers demonstrates smoking as the lifestyle risk factor. Environmental risk factors include passive smoke exposure, air pollution, and other sources of particulate inhalation.

Mutations

Genetic predisposition amplifies the risk of lung cancer, and lung adenocarcinoma is more associated than other histotypes with genetic factors. The most frequently reported somatic mutations in lung cancer are in the genes for TP53, LRP1B, KRAS, KEAP1, KMT2C, FAT4, CDKN2A, EGFR, and FAT2.

Select cell lines from the table below based on mutation, and click on genes to find relevant products (antibodies, shRNA, siRNA, primers, CRISPR plasmids) for your research application.

Table 1.Lung cancer cell lines with specific mutations

Small molecules/monoclonal antibodies

Small molecule compounds and antibodies can be used to target specific cancer cells and block tumor growth and progression. The most common drugs used to target lung cancer include:

Applications

Cancer cell lines have been at the heart of cancer research, and provide an accessible, cost-effective model for cellular behavior and response. Based on the characteristics of the cell line and experimental need, cell lines may be used in one or more applications. Some examples of application-specific use for cell lines associated with lung cancer are included below.

ECACC Lung Cancer Cell Lines

References

1.
Cancer Stat Facts: Lung and Bronchus Cancer. [Internet]. Available from: https://seer.cancer.gov/statfacts/html/lungb.
2.
Onaitis M, Hanna J. 2013. Cell of origin of lung cancer. J Carcinog. 12(1):6. https://doi.org/10.4103/1477-3163.109033
3.
Chen Y, Zhou B, Wu X, Xu J, Zhang J, Chen Y, Liang S. 2016. CCL22 and IL-37 inhibit the proliferation and epithelial-mesenchymal transition process of NSCLC A549 cells. 36(4):2017-2024. https://doi.org/10.3892/or.2016.4995
4.
Magrez A, Kasas S, Salicio V, Pasquier N, Seo JW, Celio M, Catsicas S, Schwaller B, Forró L. 2006. Cellular Toxicity of Carbon-Based Nanomaterials. Nano Lett.. 6(6):1121-1125. https://doi.org/10.1021/nl060162e
5.
Shao MXG, Nakanaga T, Nadel JA. 2004. Cigarette smoke induces MUC5AC mucin overproduction via tumor necrosis factor-?-converting enzyme in human airway epithelial (NCI-H292) cells. American Journal of Physiology-Lung Cellular and Molecular Physiology. 287(2):L420-L427. https://doi.org/10.1152/ajplung.00019.2004
6.
Sakamoto S, Inoue H, Ohba S, Kohda Y, Usami I, Masuda T, Kawada M, Nomoto A. 2015. New metastatic model of human small?cell lung cancer by orthotopic transplantation in mice. Cancer Sci. 106(4):367-374. https://doi.org/10.1111/cas.12624
7.
Smith DL, Acquaviva J, Sequeira M, Jimenez J, Zhang C, Sang J, Bates RC, Proia DA. 2015. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer. Targ Oncol. 10(2):235-245. https://doi.org/10.1007/s11523-014-0329-6
8.
Park Y, Kim D, Dai J, Zhang Z. 2015. Human bronchial epithelial BEAS-2B cells, an appropriate in vitro model to study heavy metals induced carcinogenesis. Toxicology and Applied Pharmacology. 287(3):240-245. https://doi.org/10.1016/j.taap.2015.06.008
9.
ZHAO F, HAN J, CHEN X, WANG J, WANG X, SUN J, CHEN Z. 2016. miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor. 38(1):183-191. https://doi.org/10.3892/ijmm.2016.2588
Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?